blinatumomab (100)(62)							

Structure	

DIQLTQSPAS LAVSLGQRAT ISCKASQSVD YDGDSYLNWY QQIPGQPPKL 50

LIYDASNLVS GIPPRFSGSG SGTDFTLNIH PVEKVDAATY HCQQSTEDPW 100

TFGGGTKLEI KGGGGSGGGG SGGGGSQVQL QQSGAELVRP GSSVKISCKA 150

SGYAFSSYWM NWVKQRPGQG LEWIGQIWPG DGDTNYNGKF KGKATLTADE 200

SSSTAYMQLS SLASEDSAVY FCARRETTTV GRYYYAMDYW GQGTTVTVSS 250

GGGGSDIKLQ QSGAELARPG ASVKMSCKTS GYTFTRYTMH WVKQRPGQGL 300

EWIGYINPSR GYTNYNQKFK DKATLTTDKS SSTAYMQLSS LTSEDSAVYY 350

CARYYDDHYC LDYWGQGTTL TVSSVEGGSG GSGGSGGSGG VDDIQLTQSP 400

AIMSASPGEK VTMTCRASSS VSYMNWYQQK SGTSPKRWIY DTSKVASGVP 450

YRFSGSGSGT SYSLTISSME AEDAATYYCQ QWSSNPLTFG AGTKLELKHH 500

HHHH 									 504

Disulfide bridges location / Position des ponts disulfure / 

Posiciones de los puentes disulfuro

23-92 148-222 277-351 415-479 

Glycosylation sites / Sites de glycosylation / Posiciones de
glicosilaciun

307 (but Pro in 308)

Molecular formula	C2367H3577N649O772S19

Description

immunoglobulin scFv-scFv, anti-[Homo sapiens CD19 (B lymphocyte surface
antigen B4, Leu-12)]/anti-[Homo sapiens CD3 epsilon;

(CD3E, Leu-4)] Mus musculus monoclonal antibody bispecific single chain;

Mus musculus scFv anti-CD19 [V-KAPPA (IGKV3-4-IGKJ1*01)[10.3.9] (1-111)
-tris(tetraglycyl-seryl) -VH (IGHV1-54-(IGHD)-IGHJ4*01, S123>T) [8.8.17]
(127-250)] -tetraglycyl-seryl -Musmusculus scFv anti-CD3E [VH
(IGHV1-4-(IGHD)-IGHJ2*01) [8.8.12](256-374)
-valyl-glutamyl-tetrakis(diglycyl-seryl)-diglycyl-valylaspartyl-V-KAPPA
(IGKV4-59-IGKJ5*01) [5.3.9] (393-498)] -hexahistidine

	

WHO 

International Nonproprietary Names Programme	

07/2008

9028

		

